Skip to main content

Table 1 Patients’ reported comorbidities at baseline

From: Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Comorbidity

n (%)

Dyslipidaemia

68 (42.0)

Hypertension

70 (40.3)

Anxiety

53 (32.7)

Depression

53 (32.7)

Fibromyalgia

16 (9.9)

Smoking

15 (9.3)

Diabetes

13 (8.0)

Obstructive sleep apnoea

12 (7.4)

Hypothyroidism

11 (6.8)

Tumours

10 (6.2)

Chronic obstructive pulmonary disease

7 (4.3)

Peripheral artery disease

5 (3.1)

Liver disease

5 (3.1)

Nephropathy

5 (3.1)

Cardiac ischaemic disease

4 (2.5)

Cerebral ischaemic disease

1 (0.6)

Others

31 (19.1)